Encore Medical’s IPO process faces extended SEC review delays following its September 2025 S-1 filing and March 2026 amendments, with no pricing, roadshow, or effectiveness announced as of mid-May 2026, driving the 81% market-implied probability of no closing before June. The development-stage medtech firm targets a $15 million raise at $5 per share for 3 million shares, implying a post-IPO market cap near $49 million on roughly 9.74 million shares outstanding, yet its limited trailing revenue of about $2 million and ongoing R&D losses for FDA clinical trials on septal occlusion devices temper near-term pricing upside. Micro-cap IPO conditions remain choppy amid broader market volatility, with traders assigning only 10.2% odds to a 55 million-plus close and lower probabilities to narrower buckets, reflecting the absence of recent catalysts that could accelerate effectiveness or shift sentiment before the June threshold.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoSem IPO antes de junho de 2026 81%
Mais de 55M 15.0%
45M–50M 7%
<45M 2.9%
$24,068 Vol.
$24,068 Vol.
22 abr 2026
<45M
3%
45M–50M
7%
50M–55M
8%
Mais de 55M
10%
Sem IPO antes de junho de 2026
81%
Sem IPO antes de junho de 2026 81%
Mais de 55M 15.0%
45M–50M 7%
<45M 2.9%
$24,068 Vol.
$24,068 Vol.
22 abr 2026
<45M
$7,323 Vol.
3%
45M–50M
$2,625 Vol.
7%
50M–55M
$1,823 Vol.
8%
Mais de 55M
$3,121 Vol.
10%
Sem IPO antes de junho de 2026
$9,175 Vol.
81%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Encore Medical’s IPO process faces extended SEC review delays following its September 2025 S-1 filing and March 2026 amendments, with no pricing, roadshow, or effectiveness announced as of mid-May 2026, driving the 81% market-implied probability of no closing before June. The development-stage medtech firm targets a $15 million raise at $5 per share for 3 million shares, implying a post-IPO market cap near $49 million on roughly 9.74 million shares outstanding, yet its limited trailing revenue of about $2 million and ongoing R&D losses for FDA clinical trials on septal occlusion devices temper near-term pricing upside. Micro-cap IPO conditions remain choppy amid broader market volatility, with traders assigning only 10.2% odds to a 55 million-plus close and lower probabilities to narrower buckets, reflecting the absence of recent catalysts that could accelerate effectiveness or shift sentiment before the June threshold.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercado Aberto: Apr 3, 2026, 7:59 PM ET
Volume
$24,068Data de Término
22 abr 2026Mercado Aberto
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Encore Medical’s IPO process faces extended SEC review delays following its September 2025 S-1 filing and March 2026 amendments, with no pricing, roadshow, or effectiveness announced as of mid-May 2026, driving the 81% market-implied probability of no closing before June. The development-stage medtech firm targets a $15 million raise at $5 per share for 3 million shares, implying a post-IPO market cap near $49 million on roughly 9.74 million shares outstanding, yet its limited trailing revenue of about $2 million and ongoing R&D losses for FDA clinical trials on septal occlusion devices temper near-term pricing upside. Micro-cap IPO conditions remain choppy amid broader market volatility, with traders assigning only 10.2% odds to a 55 million-plus close and lower probabilities to narrower buckets, reflecting the absence of recent catalysts that could accelerate effectiveness or shift sentiment before the June threshold.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$24,068Data de Término
22 abr 2026Mercado Aberto
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Encore Medical’s IPO process faces extended SEC review delays following its September 2025 S-1 filing and March 2026 amendments, with no pricing, roadshow, or effectiveness announced as of mid-May 2026, driving the 81% market-implied probability of no closing before June. The development-stage medtech firm targets a $15 million raise at $5 per share for 3 million shares, implying a post-IPO market cap near $49 million on roughly 9.74 million shares outstanding, yet its limited trailing revenue of about $2 million and ongoing R&D losses for FDA clinical trials on septal occlusion devices temper near-term pricing upside. Micro-cap IPO conditions remain choppy amid broader market volatility, with traders assigning only 10.2% odds to a 55 million-plus close and lower probabilities to narrower buckets, reflecting the absence of recent catalysts that could accelerate effectiveness or shift sentiment before the June threshold.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions